Application and method of PARP inhibitor Veliparib in screening BRCA1 heterozygous mutant embryos

By blocking the screening of BRCA1 heterozygous mutant embryos in the early stage of embryo development using the PARP inhibitor Veliparib, the problems of complex operation and low detection accuracy in the prior art were solved, and efficient screening of BRCA1 heterozygous mutant embryos from the protein function level was achieved. Ensures the safety and accuracy of screening.

CN118995870AActive Publication Date: 2024-11-22TONGJI HOSPITAL ATTACHED TO TONGJI MEDICAL COLLEGE HUAZHONG SCI TECH
View PDF 6 Cites 0 Cited by

Patent Information

Application Number
CN202410846664.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-06-27
Publication Date
2024-11-22
Estimated Expiration
2044-06-27

AI Technical Summary

Technical Problem

The existing pre-embryo implantation gene detection technology has problems such as complex operation, high detection cost, limited accuracy and potential embryo damage when screening BRCA1 hybrid mutant embryos, making it difficult to screen all gene defective embryos from the genetic functional level. purpose.

Method used

By blocking the inheritance of BRCA1 pathogenic genes, it uses its synergistic lethal effect to screen BRCA1 heterozygous mutant embryos in the early stage of embryo development, achieving direct and efficient screening from the protein function level, avoiding embryos during biopsy. potential damage and simplifies operational procedures.

Benefits of technology

It achieves safer, more efficient and more convenient embryo screening, ensuring the accuracy and cost-effectiveness of screening, while avoiding the impact on normal embryos, effectively blocking the development of BRCA1 heterozygous mutant embryos.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118995870A_ABST
    Figure CN118995870A_ABST
Patent Text Reader

Abstract

The invention relates to an application of a PARP inhibitor Veliparib in screening BRCA1 heterozygous mutant embryos and a method of screening BRCA1 heterozygous mutant embryos. According to the invention, a PARP inhibitor Veliparib with a low capture effect is applied to screening of BRCA1 heterozygous mutant mouse embryos, through animal experiments, a new application of 7.5 [mu] M Veliparib for selectively retarding development of BRCA1 heterozygous embryos is developed, heredity of BRCA1 pathogenic genes is blocked, and birth of BRCA1 heterozygotes in offspring is avoided. Compared with a PGT-M technology clinically applied at present, the method has the advantages that the thinking of screening mutant embryos by using gene sequences is broken through, the BRCA1 hybrid embryos with insufficient homologous recombination functions are effectively screened innovatively, directly and efficiently from the protein function level, and the method has the characteristics of simplicity in operation, high cost performance, small trauma and high accuracy.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of biotechnology, and in particular to an application and method of the PARP inhibitor Veliparib in screening out BRCA1 heterozygous mutation embryos. Background Art

[0002] Malignant tumors, as a major public health event threatening human health, have become the leading cause of death in my country. Among them, hereditary tumors, with their unique genetic background and pathogenesis, account for 5-10% of malignant tumors. Among these tumors, hereditary ovarian and breast cancer (HBOC) and the BRCA1 gene have been widely studied. Among patients with hereditary breast cancer, pathogenic mutations of BRCA1 have been detected in more than 90% of cases. The BRCA1 gene is located on human chromosome 17 and plays a vital role in cell physiological processes such as transcriptional regulation, DNA repair and cell cycle regulation. Studies have shown that pathogenic variants of BRCA1 can significantly increase the risk of ovarian cancer and breast cancer, up to 65% and 39% respectively. In addition, this gene mutation also increases the risk of patients suffering from other cancers, such as pancreatic cancer, gastric cancer and male prostate cancer.

[0003] In the general population of my country, the incidence of hereditary BRCA1 / 2 pathogenic mutations is 0.29%-1.10%. It poses a huge threat to individual and family tumor susceptibility. Fertility decision-making is an urgent and difficult issue for women carrying BRCA1 pathogenic mutations. On the one hand, they need to complete childbearing as early as possible and reduce the risk of malignant tumors through preventive surgery such as salpingo-oophorectomy; on the other hand, due to the dominant genetic characteristics of BRCA1 mutations, their offspring still have a 50% chance of carrying the same pathogenic mutation. Although prenatal diagnosis (PND) and preimplantation genetic testing (PGT) provide technical means to prevent the spread of genetic diseases, these methods still have many defects in practical application. Among them, female patients undergoing PND may experience repeated miscarriages in order to obtain a healthy fetus. In contrast, although PGT allows patients to understand the genetic mutation status of the embryo before pregnancy and make decisions in advance; however, studies have found that the use rate of PGT-M (Preimplantation Genetic Testing for Monogenic Diseases) in BRCA1 pathogenic variant carriers is only between 10% and 26%. PGT-M usually obtains embryos through in vitro fertilization and culture them in vitro. When the embryo develops to the four to eight cell stage, one or two cells (called blastomeres) of the embryo are removed using microsurgery. Then, the DNA in the cells is detected using probes or sequencing methods. The analysis results are used to judge whether the embryo has a genetic disease. The reason for the low use rate is that PGT requires more complex operations and higher testing costs, and there are still many technical problems that need to be solved. For example, there is potential embryo damage during the biopsy process, and the accuracy of the test is limited. Problems such as limited sampling and embryo mosaicism, as well as the limitations of single-cell gene analysis technology and the false positive rate of FISH testing and the low consistency rate of NGS testing may lead to deviations in the final test results. What is particularly noteworthy is that humans are currently unable to accurately interpret the functional changes caused by mutations at any site in a gene. This means that even if the accuracy of PGT-M is sufficiently improved, the data obtained from sequencing cannot represent whether the gene function is affected or not, and therefore it is impossible to achieve the goal of screening out all genetically defective embryos from the gene function level.

[0004] PARP inhibitors have been found to kill BRCA1 mutated tumor cells since 2005. They have been widely used in the maintenance treatment and post-recurrence treatment of ovarian cancer with homologous recombination repair defects. Their killing effect is mainly achieved through the "synergistic lethality" effect. At the same time, with the help of the DNA-binding effect, they are firmly bound to the DNA of the cell to help prevent the action of DNA repair enzymes, so that BRCA1 mutant tumor cells cannot smoothly repair DNA damage and die. It is also because different PARP inhibitors have different degrees of DNA-binding effects that they also have a certain impact on the physiological functions of normal cells. Patients will experience bone marrow suppression, gastrointestinal toxicity, and renal toxicity after taking the medicine. However, there is currently a lack of sufficient research and understanding of its specific effects on germ cells and embryos and its mechanism of action. Therefore, the present invention needs to be cautious about the application of Veliparib in the field of reproductive health and continue to explore its potential effects in depth. In view of this, the present invention provides the use and method of the PARP inhibitor Veliparib in screening BRCA1 heterozygous mutant embryos. Summary of the invention

[0005] The technical problem to be solved by the present invention is to provide an application and method of the PARP inhibitor Veliparib in screening BRCA1 heterozygous mutation embryos. The purpose is to screen embryos at the protein function level to achieve safer, more effective and more convenient pre-implantation embryo screening.

[0006] The technical solution of the present invention to solve the above technical problems is as follows:

[0007] First, the use of the PARP inhibitor Veliparib in the preparation of drugs for screening out BRCA1 heterozygous mutation embryos.

[0008] Among them, Veliparib, as a member of PARP inhibitors, is called Veliparib in Chinese and codenamed ABT-888. It is a new and effective PARP1 and PARP2 inhibitor. i The molecular formula is C 13 H 16 N4O .2 C l H, chemical structure formula: It is used to treat BRCA 1 mutated breast and ovarian cancers.

[0009] The beneficial effects of the present invention are as follows: the present invention applies Veliparib, a PARP inhibitor with low capture effect, to the screening of BRCA1 heterozygous mutant mouse embryos; through animal experiments: a new use of 7.5 μM Veliparib for selectively blocking the development of BRCA1 heterozygous embryos is developed, blocking the inheritance of the BRCA1 pathogenic gene, and avoiding the birth of BRCA1 heterozygotes in offspring; compared with the PGT-M technology currently used in clinical practice, the invention breaks through the idea of ​​using gene sequences to screen mutant embryos, and innovatively and more directly and efficiently screens BRCA1 heterozygous embryos with insufficient homologous recombination function from the protein function level, and has the characteristics of simple operation, high cost performance, low trauma, and high accuracy.

[0010] Based on the above technical solution, the present invention can also be improved as follows.

[0011] Furthermore, the PARP inhibitor Veliparib, through a synergistic lethal effect, utilizes the insufficient homologous recombination repair function of BRCA1 heterozygous mutant embryos in BRCA1 heterozygous mutant embryos to cause the BRCA1 heterozygous mutant embryos to accumulate more DNA damage, thereby achieving the result of blocking the development of the BRCA1 heterozygous mutant embryos.

[0012] Furthermore, the PARP inhibitor Veliparib does not affect the development and implantation of normal embryos, as well as the growth and development of offspring of normal embryonic development.

[0013] In a second aspect, a drug for screening out BRCA1 heterozygous mutation embryos comprises the PARP inhibitor Veliparib.

[0014] The actual dosage of the active ingredient (PARP inhibitor Veliparib) in the above-mentioned drug should be determined based on a variety of relevant factors, including the severity of the disease to be treated, the route of administration, the patient's age, gender, and weight. Therefore, the above-mentioned dosage should not limit the scope of protection of the present invention in any way.

[0015] Furthermore, the medicine also includes pharmaceutically acceptable excipients.

[0016] Furthermore, the medicine also includes a pharmaceutically acceptable carrier.

[0017] Furthermore, the dosage form of the drug is any one of a solution type and a microparticle dispersion type (such as a microsphere preparation, a microcapsule preparation, and a nanocapsule preparation).

[0018] In a third aspect, a screening method for eliminating BRCA1 heterozygous mutation embryos in vitro using the PARP inhibitor Veliparib is provided. The screening method is used for non-diagnostic purposes and comprises the following steps: placing in vitro fertilized embryos in a culture medium containing the PARP inhibitor Veliparib, and continuing the culture for at least 3 days until the embryos develop to the blastocyst stage.

[0019] Furthermore, the embryonic stage of the in vitro fertilization culture is a two-cell stage mouse embryo of the in vitro fertilization culture.

[0020] Furthermore, the concentration of the PARP inhibitor Veliparib in the culture medium is 7.5 μM.

[0021] Furthermore, a screening method for eliminating BRCA1 heterozygous mutation embryos in vitro using the PARP inhibitor Veliparib comprises the following specific steps: (1) constructing a BRCA1 heterozygous deletion C57BL / 6 mouse model and performing in vitro fertilization (IVF) to simulate the IVF embryo transfer process of female patients with BRCA1 mutations, and screening the obtained mouse embryos in an embryo culture medium containing the optimal concentration of Veliparib obtained by screening until the embryos reach the blastocyst stage, so that the development of embryos with BRCA1 heterozygous mutations is inhibited due to DNA repair dysfunction, while wild-type embryos can continue to develop normally through homologous recombination repair.

[0022] Compared with PGT-M, the present invention also performs drug screening of embryos during the IVF-ET process. The drug action time is from the embryo 2-cell stage to the blastocyst stage, and the mouse embryos are implanted in the mouse uterine cavity through operations that are exactly the same as the human embryo transplantation process. The killing effect of this scheme on mutant embryos and its safety on wild-type embryos are verified, and the biopsy step in the PGT-M method can be effectively avoided. While simplifying the operation, the potential damage to the embryo caused by the biopsy is also effectively avoided.

[0023] Under natural conditions, BRCA1 heterozygous embryos should account for 50% of embryos obtained by in vitro fertilization of BRCA1 heterozygous female mice and wild-type male mice, which is the same as the proportion of BRCA1 heterozygous in offspring mice. The embryos that successfully developed to the blastocyst stage after 7.5μM Veliparib drug screening were identified by nested PCR method to determine that drug treatment can effectively inhibit the development of BRCA1 heterozygous embryos and prevent them from reaching the blastocyst stage.

[0024] Furthermore, in order to simulate the clinical in vitro fertilization-embryo transfer process, the blastocysts treated with 7.5 μM Veliparib were transplanted into the uterus of surrogate ICR mice. After they became pregnant and gave birth, the genotypes of the subsequent offspring mice were further identified by PCR. Through drug screening treatment with this scheme, the birth of BRCA1 heterozygous mice was effectively avoided.

[0025] Furthermore, a method for verifying the physiological function of wild-type embryos after Veliparib screening and treatment and the safety of offspring mice developed from the embryos is provided. Specifically: the detection of the physiological function of the embryo includes indicators of embryo proliferation ability, blastocyst differentiation ability, and embryo invasion ability; the safety of the offspring includes verification of growth and development, neural reflexes, the onset of puberty, fertility, and learning and memory ability; to ensure that the drug treatment has no significant damage to the physiological function of the wild-type embryos and the healthy development of offspring mice. BRIEF DESCRIPTION OF THE DRAWINGS

[0026] Figure 1 is the chemical structural formula of Veliparib of the present invention;

[0027] Figure 2 This is a schematic diagram of the operation flow of the present invention;

[0028] Figure 3 The effect of Veliparib on the in vitro development of embryos in each group; A represents the WT group (WT♀×WT♂) and the BRCA1 group (Brca1 + / - ♀×WT♂) pictures of embryos at different stages (2-cell / 4-cell / 8-cell / morula / blastocyst stage) at different Veliparib concentrations; B is a comparison of embryo survival curves between the WT group and the BRCA1 group at different Veliparib concentrations;

[0029] Figure 4 is the proportion of blastocyst genotypes in each group after Veliparib treatment of the present invention; wherein A is the electrophoresis result of genotype detection of blastocysts in the control group and the Veliparib treatment group using the semi-nested PCR method, in which the white numbers represent wild-type embryos, the yellow numbers represent BRCA1 heterozygous embryos, and the green "+" represents the positive control; B is the results of genotype detection and identification of the two groups of embryos;

[0030] Figure 5 The genotype of the offspring mice after blastocyst transplantation after Veliparib treatment of the present invention;

[0031] Figure 6It is a detection of growth and development related indicators of offspring after embryo transplantation in the Veliparib treatment group and the control group of the present invention; wherein A is a comparison of weight changes of offspring mice in the Veliparib treatment group and the control group at multiple time points; B is a comparison of the average percentages of bilateral ear opening of the two groups of mice; C is a comparison of the average percentages of mandibular tooth eruption of the two groups of mice; D is a comparison of the average percentages of eye opening of the two groups of mice;

[0032] Figure 7 The present invention is a detection of the related indexes of the offspring nerve reflex after two groups of embryo transplantation; wherein A is a comparison of the righting reflex of the offspring mice of the Veliparib treatment group and the control group; B is a comparison of the cliff avoidance test between the two groups of mice; C is a comparison of the negative geotaxis test between the two groups of mice;

[0033] Figure 8 The present invention is to detect the related indicators of the onset of puberty in the offspring after the two groups of embryo transplantation; wherein A is the comparison of testicular descent of the offspring female mice in the Veliparib treatment group and the control group; B is the comparison of vaginal opening of the offspring male mice between the two groups;

[0034] Fig. 9 The invention detects the related indexes of offspring reproductive ability after two groups of embryo transplantation; wherein, A is the comparison of sperm concentration of male mice in the offspring of the Veliparib treatment group and the control group; B is the comparison of sperm motility of the two groups of mice; C is the comparison of the percentage of forward-moving sperm of the two groups of mice; D is the comparison of pregnancy rate of female mice in the offspring of the Veliparib treatment group and the control group after natural mating; E is the comparison of the average litter size of female mice in the two groups; F is the comparison of live birth rate of female mice in the two groups;

[0035] Fig.10 The present invention is a detection of related indicators of learning and memory ability of offspring after two groups of embryo transplantation; wherein A is a representative trajectory image of offspring mice in the Veliparib treatment group and the control group; B is a comparison of the number of times the two groups of offspring mice cross the platform position; C is a comparison of the percentage of the time the two groups of offspring mice stay in the quadrant where the platform is located. DETAILED DESCRIPTION

[0036] The principles and features of the present invention are described below, and the examples are only used to explain the present invention and are not used to limit the scope of the present invention. If no specific technology or conditions are specified in the embodiments, the technology or conditions described in the literature in this field or the product instructions are used. If the manufacturer of the reagents or instruments used is not specified, they are all conventional products that can be purchased through regular channels.

[0037] Example

[0038] 1. Experimental reagents and materials

[0039] 1.1 Main Reagents

[0040] Veliparib( Figure 1 , Selleck), mHTF embryo culture medium (cosmo bio), KSOM embryo culture medium (cosmobio), pregnant mare serum gonadotropin (Beijing Solebao Company), chorionic gonadotropin for injection (Anhui Fengyuan Pharmaceutical Company), ready-to-use normal goat serum (Boster Biological), TritonX-100 (Beijing Solebao Company), 75% ethanol (Xilong Science), bovine serum albumin (Sevier Biological), DAPI staining reagent (Sevier Biological), Red nucleic acid gel dye 10,000× (MCE), sodium pentobarbital (Sigma-Aldrich), 4% paraformaldehyde (Sevier Biological), agarose (Beijing Baijing Biological), and mineral oil for culture (Sigma-Aldrich).

[0041] 1.2 Main instruments

[0042] Three-gas incubator (COOK), electronic balance (Mettler Toledo), electrophoresis apparatus (Bio-Rad), mouth pipette (Drummond scientific), microscope hot stage (Guangzhou Mingmei Technology Co., Ltd.), upright optical microscope (Olympus), fluorescence inverted microscope (Zeiss), high-speed low-temperature centrifuge (Heal Force Co., Ltd.), PCR instrument (Bio-Rad), etc.

[0043] 1.3 Experimental animals

[0044] The experimental research subjects were BRCA1 heterozygous deletion C57BL / 6 mice, and the transgenic mice were constructed by Saiye Biotechnology Co., Ltd. The specific methods were:

[0045] The donor vector containing the "WPRE-rBGpA" cassette, gRNA targeting the mouse BRCA1 gene (CATTTTGTACTTCTTGAATTTGG, SEQ ID NO: 1) and Cas9 mRNA were co-injected into C57BL / 6 mouse fertilized eggs to produce offspring mice with BRCA1 functional deficiency. The genotype of the F0 primary generation mice was identified by PCR and sequenced. The F0 primary generation mice were hybridized with wild-type C57 mice for germline passage and subsequent animal experiments. The C57BL / 6 mice used for in vitro fertilization experiments were 4 weeks old (w) for female mice and 8 weeks old (w) for male mice.

[0046] All mice used in the study of this invention were kept in the SPF animal room of the Animal Experiment Center of the Research Building of Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology, with a fixed light-dark cycle, in line with the daily rhythm of mice, and appropriate temperature and humidity. Approved by the Ethics Committee of Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology (Ethics Number: TJH-202110009).

[0047] 2. Experimental methods

[0048] Schematic diagram as Figure 2 shown.

[0049] 2.1 Experimental Grouping

[0050] Forty 4-week-old BRCA1 heterozygous female mice and ten 10-week-old wild-type (WT) male mice were used to obtain embryos by in vitro fertilization. The 2-cell embryos were randomly divided into two groups, namely, the Veliparib-treated group and the blank control group. The Veliparib drug concentration in the culture medium of the Veliparib-treated group was 7.5 μM.

[0051] 2.2 Mouse genotype identification

[0052] DNA extraction: Cut 1-2 mm of the mouse tail or toes and place them in a 1.5 mL EP tube. Use DNA extraction lysis buffer to extract animal tissue DNA. Add 100 μL Lysis Buffer for PCR and 1 μL Proteinase K to each tube according to the instructions and mix thoroughly. Heat at 60°C in a metal bath for 5 minutes, then at 98°C for 2 minutes. After the reaction is complete, transfer the supernatant to a new centrifuge tube and place it on ice.

[0053] PCR: Take 2 μL of supernatant as DNA template for PCR reaction. Prepare the corresponding PCR mixture in eight tubes. The PCR reaction system is as follows:

[0054] Table 1 PCR reaction system

[0055]

[0056] Table 2 PCR primer sequences are as follows

[0057]

[0058] Mix well and centrifuge. Perform PCR reaction in a PCR instrument as follows:

[0059] Table 3 PCR reaction process

[0060]

[0061] Agarose gel electrophoresis: Dissolve 2g of agarose powder in 100mL of 0.5×TBE electrophoresis buffer and heat until completely dissolved. Add 10μL of Red nucleic acid gel dye (10,000×), pour into the gel-making mold, and let stand at room temperature for 30 minutes. Add PCR products and markers to the sample wells of the agarose gel. Usually 5-10μL of sample is added to each sample well. Turn on the power supply, adjust the voltage to 100V, and the time is 30 minutes to allow the DNA fragments to move toward the positive electrode under the action of the electric field.

[0062] Observation results: After electrophoresis, place the gel in a gel imaging system to observe and record the results.

[0063] 2.3 In vitro fertilization (IVF) and embryo treatment with Veliparib:

[0064] Ovulation induction in female mice: 4-week-old BRCA1 heterozygous C57BL / 6 female mice were used for ovulation induction. Each mouse was intraperitoneally injected with 5 IU of pregnant mare serum gonadotropin (PMSG), and 48 hours later, 5 IU of chorionic gonadotropin (HCG) was injected. After 14-16 hours, the mice were killed by cervical dislocation and bilateral oviducts were removed. Under a stereomicroscope, the transparent enlarged parts of the bilateral oviducts of the mice were found, and the cumulus-oocyte complex (COC) was torn open with forceps to obtain the COC and transferred into mHTF;

[0065] Sperm acquisition and capacitation: 10-week-old C57BL / 6 male mice were killed, and the bilateral epididymal caudae were obtained. Sperm were squeezed out from the vas deferens under a microscope and transferred into mHTF culture medium. After capacitation for 1 hour, they were used for fertilization.

[0066] In vitro fertilization: Add 3-4 μL of capacitated sperm to each mHTF droplet and place in a three-gas incubator for fertilization for 4-6 hours. After fertilization, transfer the embryos to KSOM embryo culture medium;

[0067] Embryo Veliparib treatment: Two-cell embryos were collected the next day (24 h after fertilization) and randomly divided into a control group and a Veliparib-treated group. They were transferred into KSOM culture medium and KSOM culture medium containing 7.5 μM Veliparib for further culture.

[0068] 2.4 Blastocyst-uterus transfer

[0069] Prepare pseudo-pregnant female mice: Select 8-week-old ICR female mice with a history of reproduction, good maternal instinct, and in estrus and put them in cages with ligated mice (female: male = 2:1). Observe them the next morning. Those with vaginal plugs are pseudo-pregnant mice. They are randomly divided into control group and experimental group for transplantation surrogacy.

[0070] Mouse anesthesia: On the 3.5th day after vaginal suppository administration, 1% sodium pentobarbital solution was prepared with normal saline as an anesthetic drug, and injected intraperitoneally at a dose of 50 mg / kg according to the weight of the mouse. After injection, the mouse was left to stand for 10 minutes to ensure that the mouse was fully anesthetized before subsequent surgical operations.

[0071] Disinfection and local infiltration anesthesia: Shave the back of the anesthetized female mouse, fix it on the operating table in a prone position, and wrap its head with a towel or cloth to prevent it from waking up during the operation. Disinfect the back of the female mouse with iodine and alcohol;

[0072] Incision: Make a small cut on one side of the spine on the back of the mouse, cut the peritoneum, and expose the ovaries and uterus of the surrogate mouse. The uterus is usually located deep in the abdominal cavity, close to the spine.

[0073] Embryo preparation: Take out the embryos from the KSOM embryo culture medium and use a microscope to check the quality and development stage of the embryos. Select high-quality blastocysts with obvious blastocyst cavity and hatched as the transplant objects, and transfer the blastocysts to the pre-balanced MⅡ culture medium;

[0074] Embryo transplantation: The embryo transplantation process requires the cooperation of two people. One person uses forceps to pull the ovaries, fallopian tubes and uterus out of the peritoneum. Under a stereo microscope, accurately find the connection between the uterus and the fallopian tubes, which is the uterine horn. Use an insulin syringe to gently pierce a small hole in the uterine horn. The other person uses a mouth pipette to suck the blastocyst into the capillary glass tube under the microscope, sucking as little liquid as possible, inserting the capillary glass tube loaded with the blastocyst into the small hole in the uterine horn, and gently blowing to allow the blastocyst in the capillary glass tube to enter the uterus. Be careful to avoid bringing in excess culture medium or bubbles. The capillary glass tube should not be inserted too deep to avoid damaging the endometrium or causing blockage of the tube. After completion, check whether there are any remaining embryos in the capillary glass tube.

[0075] Suturing the wound: After the transplant is completed, carefully put the ovaries, fallopian tubes and uterus back into the peritoneum, and use surgical sutures to suture the peritoneum and skin layer by layer to ensure that the wound is neat and tight to promote postoperative recovery.

[0076] Postoperative care: Place the mice in a warm and dry environment after surgery, and return them to the animal room after they fully wake up. Pay attention to the mice's condition and reaction, keep the surgical site clean and dry, and avoid infection and other complications. At the same time, give them appropriate nutrition and water supplements to promote wound healing and physical recovery.

[0077] 2.5 Experimental observation indicators

[0078] 2.5.1 IVF embryo development capacity in vitro

[0079] Observation and recording results: Use ZEN 2012 software to take pictures and count at 48, 60, 72, and 96 hours after fertilization, and observe and count the embryos reaching the four-cell, eight-cell, morula, and blastocyst stage. The blastocyst cavity observed under a microscope is used to determine that the embryo has reached the blastocyst stage. Main parameter calculation method:

[0080] Blastocyst rate = number of blastocysts / number of two-cell embryos × 100%;

[0081] Fertilization rate = number of two-cell embryos / number of oocytes × 100%;

[0082] Embryo survival rate = number of embryos at this stage (four-cell, eight-cell, mulberry stage) / number of two-cell embryos × 100%;

[0083] 2.5.2 Observation and recording of birth conditions of offspring mice

[0084] Starting from the 14th day after transplantation, the pregnancy and delivery of the surrogate female mice were observed daily. On the day of the birth of the offspring mice, the total number of mice born, the number of live births, and the number of stillbirths were counted, and the weight of each mouse was weighed and the gender was checked. The birth outcome parameters of the offspring mice after transplantation were calculated as follows:

[0085] Pregnancy rate (%) = number of pregnant mice after transplantation / total number of transplanted mice × 100%;

[0086] Live birth rate (%) = number of live births / total number of litters × 100%;

[0087] Birth rate (%) = total number of litters / number of embryos transferred × 100%;

[0088] 2.5.3 Identification of blastocyst genotype by semi-nested PCR

[0089] According to the experimental plan, after the mixed embryos were transferred to Veliparib for treatment for 72 hours, the embryos that successfully reached the blastocyst stage were collected for genotype identification to determine the killing effect of in vitro drug treatment on BRCA1 heterozygous embryos. However, due to the small number of blastocyst cells and low DNA content, the semi-nested PCR method was selected to detect its genotype. This method requires two rounds of PCR amplification and the design of three primers. First, the first pair of primers F3R6 were used to perform the first round of amplification of the blastocyst DNA, and then the first round of PCR products were used as templates for the second round of PCR amplification. The second round of primers was F3R5. The primer sequences are as follows:

[0090] Table 4 Primer sequences

[0091]

[0092] DNA extraction: Use DNA extraction lysis buffer to extract embryonic DNA. According to the instructions, add 10μL LysisBuffer for PCR and 0.1μL Proteinase K to each tube, mix thoroughly, place in an eight-tube tube, use a mouth pipette to suck a single blastocyst and blow it into the liquid. After a slight centrifugation, heat it in a PCR instrument at 60℃ for 5 minutes, then at 98℃ for 2 minutes. The reaction is completed and used as the first round of PCR template;

[0093] F3R6 was used as the first round PCR primer, and the reaction conditions were consistent with conventional PCR. The reaction system was as follows;

[0094] Table 5 Reaction system

[0095]

[0096] After the first round of PCR, 5 μL of PCR product was taken as the template for the second round of PCR. F3R5 was used as the second round of PCR primer. The reaction conditions were consistent with those of conventional PCR. The reaction system was as follows, and BRCA1 heterozygous mouse tail DNA was added as a positive control:

[0097] Table 6 Reaction system

[0098]

[0099] Agarose gel electrophoresis: After the reaction is completed, the second round of PCR products are loaded for agarose gel electrophoresis. The experimental operation and conditions are consistent with conventional PCR. After the electrophoresis is completed, the gel is placed in a gel imaging system to observe and record the results.

[0100] 2.5.4 Safety testing of offspring mice

[0101] (1) Female mouse fertility test

[0102] The female mice in the control group and the Veliparib treatment group were caged with 10w normal fertility male mice at a ratio of 2:1. After mating for 1 week, they were separated and raised individually. The pregnancy of the female mice was checked by visual and tactile methods starting from the 14th day after caged. The birth was observed every day. The number of pups, stillbirths and live births of each female mouse was recorded on the day of birth.

[0103] (2) Cliff avoidance test

[0104] The cliff avoidance test is a classic method for evaluating the stereoscopic vision and perceptual ability of rodents. The specific operation is as follows: the experimenter places an 8-day-old mouse on an acrylic board about 30 cm above the ground, with the mouse's head and forelimbs exposed on the edge of the board. The experimenter lets go and starts timing. If the mouse turns more than 180° on its own within 30 seconds, it is considered a positive result in the cliff avoidance test. If the mouse falls off the platform or does not turn around, it is considered a negative result.

[0105] (3) Negative geotaxis experiment

[0106] Rodents (such as rats and mice) are born with the ability to rotate from a head-down position to a head-up position on an inclined plane. This reaction is called negative geotaxis. This natural reflex ability is acquired by normal pups in the second week shortly after birth. The negative geotaxis test is a key test to evaluate the reflex ability, motor coordination, vestibular system and cerebellar functional integrity of rodent pups. Through this experiment, researchers can gain a deeper understanding of the characteristics of rodents in terms of neurodevelopment and behavioral performance. The specific operation method of the negative geotaxis test is as follows: On the 9th day after the mouse was born, the experimenter used an acrylic board to build a 45° inclined plane, placed the pup head down on the board, and the experimenter let go and started timing at the same time. If the mouse turned its head more than 180° within 30 seconds, it was considered positive for the negative geotaxis test. If the mouse slipped off the platform or did not turn its head, it was considered negative.

[0107] (4) Righting reflex

[0108] The righting reaction is one of the classic experiments used to check whether the vision, vestibular system, pressure receptors or tactile receptors of the limbs, and position sense functions of experimental animals are normal. The operation method is as follows: On the 10th day after the mouse was born, the experimenter first gently fixed the mouse on its back with its limbs facing up on a smooth and stable plane with both hands to ensure that the mouse's body does not slide or move. Then, the experimenter releases his hands and starts timing at the same time. The experimenter uses both hands to fix the mouse on its back with its limbs facing up on the plane, and starts timing at the same time when he releases his hands. If the mouse can quickly adjust its body position within 2 seconds and turn over from the supine position to a normal crawling posture, it is considered a positive righting test, otherwise it is negative.

[0109] (5) Mouse ears open

[0110] Observe the opening of the ears of mice from the 4th to the 7th day after birth. When the auricles on both sides of the mice are clearly separated from the scalp, it is considered to be positive for opening of the ears. Use a magnifying glass to observe carefully and record the percentage of mice with positive ears in a litter every day. During the observation process, be patient, move gently, and avoid overstimulating or disturbing the mice.

[0111] (6) Eruption of mandibular teeth in mice

[0112] The proportion of mice with positive mandibular tooth eruption in the offspring mice was observed and recorded daily from the 11th day to the 14th day after birth. The operation method is as follows: the experimenter gently fixes the mouse with one hand so that its head is facing up, and gently moves the lower jaw of the young mouse with the other hand. If the mandibular incisor of the mouse is carefully observed to be completely erupted from the gums, it is considered to be positive for mandibular tooth eruption.

[0113] (7) The mouse opened both eyes

[0114] The opening of both eyes of the mice was observed from the 16th day after birth until the 20th day. The observation criteria were as follows: in a quiet, bright environment without direct strong light sources, the bilateral eyelids of the mice were completely separated in their natural state, the eyeballs were clearly visible, and there was no secretion or adhesion. This was considered a positive test for both eyes to be open. The proportion of mice with positive results for both eyes to be open was recorded every day.

[0115] (8) Female rat vagina opens

[0116] Vaginal opening is a sign of the onset of puberty in female mice. The opening of the vagina of female mice was observed on the 28th day after birth. The specific operation method is as follows: the experimenter gently lifts the mouse tail with one hand and gently flicks the vaginal opening with a cotton swab with the other hand to observe whether the vaginal opening is completely separated from the surrounding skin without adhesion, and the proportion of mice with positive vaginal opening is recorded every day.

[0117] (9) Testicular descent in male rats

[0118] The testicular descent of male mice was observed and recorded starting 22 days after birth. The specific operation method was as follows: the experimenter held the mouse with one hand and gently pressed and touched the scrotum of the male mouse with the other hand to feel whether the male mouse testicles had completely fallen from the abdominal cavity into the scrotum. Be careful not to squeeze the male mouse testicles downward, and record the proportion of mice with positive testicular descent every day.

[0119] (10) Morris water maze

[0120] Build the experimental facilities: put water in a circular bathtub, add skim milk powder to the water to make the platform invisible, lower the water level so that the platform is about 0.5cm-1cm below the water surface, and paste direction reminders inside the four quadrants of the pool. Ensure that all equipment (such as the pool, platform, camera, computer, etc.) are working properly, and adjust the water temperature to 22-25 degrees Celsius;

[0121] Acquisition training stage: The first five days are the training period. The mice are gently placed in the water facing the pool wall. Each mouse is placed in 4 quadrants every day. The experiment is repeated 4 times. The mice are allowed to explore freely in the water for 1 minute. If the mouse finds the platform within 1 minute, it is allowed to learn to stay on the platform for 15 seconds before being fished out. If the mouse fails to find the platform within 1 minute, it is artificially guided to the platform and allowed to learn to stay on the platform for 15 seconds before being fished out.

[0122] Formal testing phase: The sixth day was the formal test. The platform was removed and the mice were placed in the water from the quadrant opposite the platform. They were allowed to swim freely in the water maze for 1 minute. The ANY-maze system and camera were used to monitor the swimming trajectory of the mice and record their performance during the testing phase, including the number of times they passed the platform and the swimming time in the quadrant where the original platform was located.

[0123] (11) Monitoring of mouse body weight curve

[0124] Weigh the mice on the 1st, 4th, 7th, and 14th day after birth. The steps are as follows: plug the electronic balance into the power supply, turn it on, and after the reading stabilizes, put the weighing box on and adjust it to zero. Gently grab the offspring mice of each group and put them in the weighing box. After the value stabilizes, read and record the value.

[0125] (12) Male mouse sperm detection

[0126] Prepare a 37℃ water bath, prepare 1.5mL EP tubes, add 1000μL PBS to each tube after marking, and put it in the water bath to preheat for 30 minutes. Take a male mouse of about 8 weeks, kill it by breaking the neck, cut the abdominal cavity, take the bilateral epididymal tails, put them in PBS preheated at 37℃, use clean ophthalmic scissors to reach into the EP tube, and cut the tissue into pieces. Put the EP tube in a water bath and incubate at 37℃ for 30 minutes. Take 100μL of supernatant and add it to a new EP tube pre-filled with 100μL paraformaldehyde at a ratio of 1:1. Fix it at room temperature for 30 minutes and use an automatic cell counter to record the sperm concentration. Take a 10μl supernatant smear, drop it to the center of the slide, gently cover it with a coverslip and observe it under a microscope. Select multiple fields of view to count the number of forward-moving sperm, non-forward-moving sperm, and immotile sperm. Count 200 sperm for each mouse. After two counts, take the average value to calculate the proportion of each type of sperm.

[0127] 2.6 Experimental data analysis

[0128] All measurements were repeated three or more times independently, and the results were expressed as mean ± SD (standard deviation). Statistical analysis was performed using Graphpad Prism 9.0 software (San Diego, CA, USA). The mean values ​​between the Veliparib-treated group and the control group were compared using the independent sample Student's t-test. The significance of the difference in rate between the two groups was tested using the chi-square test, and P < 0.05 was considered statistically significant.

[0129] 3. Experimental results

[0130] 3.1 Effect of Veliparib on the in vitro development of embryos in each group

[0131] In order to verify whether Veliparib has the ability to screen embryos carrying BRCA1 heterozygous mutations, the present invention uses in vitro fertilization (IVF) technology to collect wild-type (WT) and BRCA1 mutant mouse embryos. These embryos were then placed in KSOM medium containing different concentration gradients of Veliparib (0μM, 2.5μM, 5μM, 7.5μM, 10μM,) for culture. During the experiment, the present invention set multiple time points to observe and record the development of embryos in the WT group and the BRCA1 group. The present invention closely monitors the development process of each embryo in order to discover the different effects of Veliparib on these two groups of embryos.

[0132] like Figure 3 As shown in (A and B), the experimental results show that Veliparib has a certain adverse effect on the early development of embryos in both the wild-type group and the BRCA1 group. And Veliparib has a concentration-dependent inhibitory effect on embryo development. However, it is worth noting that compared with the WT group, the embryos in the BRCA1 group showed higher sensitivity to the same concentration of Veliparib. Specifically, at the same Veliparib concentration, more embryos in the BRCA1 group were blocked from developing and could not continue to develop normally.

[0133] In order to find the appropriate screening concentration to distinguish BRCA1 heterozygous embryos from wild-type embryos, the present invention conducted further statistical analysis and plotted the survival curve of embryo development ( Figure 3 In the absence of Veliparib, there was no significant difference in the survival curves between BRCA1 embryos and wild-type embryos ( Figure 3A and B, P = 0.0702). However, when treated with the same concentration of Veliparib, more embryos in the BRCA1 group delayed or stopped developing, and the difference in the survival curves between the two groups became more obvious as the concentration of Veliparib increased. When the concentration of Veliparib reached 7.5 μM, the survival curves of the two groups showed a significant difference (P < 0.001).

[0134] 3.2 Embryo genotypes before and after Veliparib in vitro screening

[0135] First, oocytes from BRCA1 heterozygous female mice were collected and in vitro fertilized with sperm from wild-type male mice. All two-cell embryos were randomly divided into a control group and a Veliparib treatment group (7.5 μM). The genotypes of embryos that reached the blastocyst stage were collected 96 hours after fertilization and identified by semi-nested PCR. The results are shown in Figure 2. Figure 4 As shown in A and B. The present invention found that 45.2% (14 / 31) of the blastocysts in the control group not treated with Veliparib were BRCA1 heterozygous embryos. This distribution is expected and confirms that heterozygous female mouse oocytes contain the same number of wild-type and mutant oocytes, and have similar oocyte quality and developmental capacity. Among the blastocysts in the Veliparib-treated group, only 3.6% (1 / 28) of the blastocysts were BRCA1 heterozygous embryos, and the remaining blastocysts were all wild-type. These results indicate that treatment with 7.5 μM Veliparib can effectively prevent BRCA1 heterozygous embryos from forming blastocysts.

[0136] 3.3 Proportion of offspring genotypes after embryo transfer before and after Veliparib in vitro screening

[0137] After verifying that Veliparib can effectively block the development of BRCA1 heterozygous embryos in vitro, the present invention further explored whether this screening scheme can effectively prevent the birth of BRCA1 heterozygous mice at the individual level through blastocyst-uterine transplantation. The present invention uses ICR mice as surrogate mice to conduct blastocyst-uterine transplantation experiments to explore the screening efficacy of the Veliparib scheme. A total of 32 surrogate ICR mice in the Control group underwent embryo transplantation surgery, of which 8 successfully gave birth to offspring. A total of 35 surrogate ICR mice in the Veliparib treatment group underwent embryo transplantation surgery, and 8 of them also successfully became pregnant and gave birth to offspring.

[0138] The results of the identification of the genotypes of the offspring mice are shown in Table 7 and Figure 5As shown. The present invention first explored the genotype of the offspring produced under natural mating conditions. Among the offspring produced by natural mating of 4 pairs of BRCA1 heterozygous female mice and WT male mice, 18 (47.4%) were BRCA1 heterozygous (including 1 stillbirth) and 20 (52.6%) were wild-type. This result is consistent with the dominant inheritance characteristics of the BRCA1 gene, and about 50% of the offspring carry BRCA1 heterozygous mutations. A total of 33 offspring mice were born in the control group, of which 18 (54.5%) were wild-type (including 1 stillbirth) and 15 (45.5%) were BRCA1 heterozygous (including 1 stillbirth). A total of 31 offspring were born in the 7.5μM Vilaparib-treated group, all of which were wild-type (including 2 stillbirths), and no BRCA1 heterozygous mice were born, whether live births or stillbirths. These results strongly demonstrate the effectiveness of the screening scheme of the present invention.

[0139] Table 7 Genotype identification results of F1 generation mice produced by transplanted pregnant mice

[0140]

[0141] 3.4 Embryo transfer related parameters

[0142] In order to preliminarily explore whether Veliparib treatment affects the embryo's implantation and pregnancy ability, the present invention further counted the pregnancy-related parameters after transplantation in the Veliparib treatment group and the Control group, as shown in Table 8. The present invention found that there was no significant difference in the average litter size (4.13 vs 3.88, P = 0.23) and the average pregnancy time (18.00 vs 18.38, P = 0.42) between the two groups. However, under the premise that the number of transplanted embryos in the two groups was similar (9.63 vs 10.13, P = 0.13), the litter rate of the Control group was higher than that of the Veliparib treatment group (41.91% vs 34.91%, P < 0.05). Combined with the results of in vitro genotyping, a reasonable explanation is that when Veliparib-treated embryos are transplanted, although most of the transplanted blastocysts are wild-type, some blastocysts carrying BRCA1 heterozygous mutations are still transferred to the uterus. Due to the defect of its DNA damage repair function, it is impossible to complete the subsequent implantation and embryo growth and development normally, so the number of offspring formed is reduced compared to the previous one. There was no significant difference in live birth rate between the two groups (94.38% vs 92.71%, P = 0.79). These results preliminarily confirmed that Veliparib treatment did not affect the implantation of wild-type embryos after screening and the normal pregnancy process.

[0143] Table 8 Comparison of parameters related to embryo transfer and pregnancy outcomes

[0144]

[0145] Note: All data in each group are expressed as mean ± standard deviation. * Compared with the Control group, the difference was statistically significant. * P<0.05.

[0146] 3.5 Safety testing of F1 offspring after veliparib treatment

[0147] In terms of offspring safety, further safety assessments were conducted on offspring mice produced after transplantation in the Veliparib-treated group and the Control group to test whether their physical development (weight changes, ear opening, eye opening, lower incisor eruption), puberty sexual maturity (vaginal opening in female mice, testicular descent in male mice), reproductive function (natural mating in female mice, sperm testing in male mice), neurodevelopment (cliff avoidance, negative flexion, righting reflex), and learning and memory (Morris water maze) were normal. Figure 6 Medium AD, Figure 7 Among A and B, Figure 8 Middle AB, Fig. 9 Medium AF, and Fig.10 As shown in Figures AC, except that the eruption rate of lower incisors in the Veliparib-treated group was slightly lower than that in the Control group on day 13 after birth (P = 0.0244), there were no significant differences in the physical development, pubertal sexual maturity, reproductive function, neural development, learning and memory and other offspring safety indicators between the two groups of mice (P > 0.05). Overall, Veliparib treatment did not significantly affect the physiological functions of wild-type blastocysts and the behavioral performance of offspring mice, which provides strong support for the safety of this program in clinical applications.

[0148] In summary, the present invention constructs a C57BL / 6 mouse model with a BRCA1 heterozygous deletion, performs in vitro fertilization (IVF) to obtain mouse embryos, and performs screening and treatment in an embryo culture medium containing Veliparib; Veliparib, with its unique chemical structure and mechanism of action, can effectively inhibit the development of BRCA1 heterozygous mutation embryos without affecting wild-type embryos; the present invention can screen and block BRCA1 heterozygous mutation embryos in vitro to avoid the inheritance of pathogenic genes to offspring, and provides a new possibility for women carrying BRCA1 mutations to avoid inheriting pathogenic genes to offspring, which has important clinical application value.

[0149] Although the embodiments of the present invention have been shown and described above, it is to be understood that the above embodiments are exemplary and are not to be construed as limitations of the present invention. A person skilled in the art may change, modify, replace and vary the above embodiments within the scope of the present invention.

Claims

1. Application of PARP inhibitor Veliparib in the preparation of drugs for screening out BRCA1 heterozygous mutation embryos.

2. The use according to claim 1, characterized in that: The PARP inhibitor Veliparib, at a specific dose and during a specific embryonic development period, acts through a synergistic lethal effect, taking advantage of the insufficient homologous recombination repair function of BRCA1 heterozygous mutant embryos in BRCA1 heterozygous mutant embryos, causing the BRCA1 heterozygous mutant embryos to accumulate more DNA damage, thereby achieving the result of blocking the development of the BRCA1 heterozygous mutant embryos.

3. The use according to claim 1, characterized in that: The direct effect of the PARP inhibitor Veliparib at a specific dose on in vitro culture of embryos at a specific developmental period does not affect the development and implantation of normal embryos, as well as the growth and development of offspring of normal embryonic development.

4. A drug for screening out BRCA1 heterozygous mutation embryos, characterized in that: The drug includes the PARP inhibitor Veliparib according to any one of claims 1 to 3.

5. A drug for screening out BRCA1 heterozygous mutation embryos according to claim 4, characterized in that: The medicine also includes pharmaceutically acceptable excipients.

6. The drug for screening BRCA1 heterozygous mutation embryos according to claim 4, characterized in that: The medicine also includes a pharmaceutically acceptable carrier.

7. The drug for screening out BRCA1 heterozygous mutation embryos according to claim 4, characterized in that: The dosage form of the drug is any one of a solution type and a microparticle dispersion type.

8. A method for screening BRCA1 heterozygous mutant embryos in vitro using the PARP inhibitor Veliparib, wherein the screening method is used for non-diagnostic purposes, characterized in that: The method comprises the following steps: placing the in vitro fertilized embryo into a culture medium containing the PARP inhibitor Veliparib at a specific concentration as claimed in any one of claims 1 to 3, and continuing the culture for at least 3 days until the embryo develops to the blastocyst stage.

9. A method for screening BRCA1 heterozygous mutant embryos in vitro using the PARP inhibitor Veliparib according to claim 8, characterized in that: The initial drug action time of the embryo cultured by in vitro fertilization is the mouse embryo at the two-cell stage of in vitro fertilization.

10. A method for screening BRCA1 heterozygous mutant embryos in vitro using the PARP inhibitor Veliparib according to claim 8, characterized in that: The specific concentration of the PARP inhibitor Veliparib in the culture medium was 7.5 μM.

Citation Information

Patent Citations

  • Use of PARP inhibitors to treat breast or ovarian cancer patients showing a loss of heterozygosity

    CN105917007A

  • Application of PARP inhibitor in promotion of directional entoderm generation

    CN108938634A

  • KUB5 / HERA as a determinant of sensitivity to DNA damage

    US20180057888A1

  • Computational modeling of loss of function based on allelic frequency

    US20230360727A1

  • Embryonic pluripotent cancer stem cells, their preparation and use

    WO2010067333A1